Targeting mechanisms that cause prostate cancer to resist treatment
Official title: Overcoming mechanisms of PTPN1 driving therapy- and castration- resistant prostate cancer with novel theranostics
Funded at Ut Southwestern Medical Center · NIH-11020113 · Data updated 2026-11-12
This study is looking at how a specific protein might help prostate cancer become harder to treat after hormone therapy, with the hope of finding new ways to improve treatment for patients facing this tough challenge.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $472,458 |
| NIH project number | 1R01CA295762-01 |
| Project ID | NIH-11020113 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with advanced prostate cancer, particularly those who have developed resistance to hormonal therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who have not undergone hormonal therapy may not benefit from this research.
What this research studies
This research investigates the molecular mechanisms behind therapy- and castration-resistant prostate cancer (t-CRPC), which is a major cause of mortality in prostate cancer patients. The study focuses on the role of the protein tyrosine phosphatase non-receptor 1 (PTPN1) in the transition of androgen-dependent prostate cancer cells to a more aggressive neuroendocrine phenotype. By using tissue culture and animal models, the researchers aim to understand how anti-androgen therapies influence PTPN1 expression and contribute to treatment resistance. The ultimate goal is to identify new therapeutic targets that could improve patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that prolong survival for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promise in targeting molecular mechanisms in prostate cancer, but this specific approach focusing on PTPN1 is relatively novel.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Hsieh, Jer-Tsong — Ut Southwestern Medical Center
- Study coordinator: Hsieh, Jer-Tsong
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.